Vir Biotechnology, Inc. today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) ...

Coffee is beloved worldwide for its rich flavor and energizing effects, but recent research points to another potential ...

The new company has also raised $75 million that will support the development of epigenetic editing therapies for hepatitis B ...

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune ...

As the end of the year approaches, drinking more often than usual, such as dinners and gatherings, often leads to heavy drinking. Excessive drinking harms l ...

From skid marks on China’s third aircraft carrier to possible ‘cure’ for hepatitis B, here’s a round-up from today’s China ...

Aligos Therapeutics focuses on ALG-000184 for CHB and ALG-055009 for MASH, targeting large, underserved markets with growing ...

Two Boston-area biotechs are shedding staff and merging together to form a new genetic medicines company. | Chroma Medicines ...

Drug combination reaches key threshold for ‘functional cure’ of chronic liver infection that affects more than 250 million ...

Hepatitis B virus (HBV) infection contributes to hepatocellular carcinoma (HCC) tumorigenesis, drug resistance, and recurrence, although the ...

Researchers have uncovered a significant mechanism involved in liver fibrosis. Their findings have been published in the ...

Cryo-electron microscopy reveals the structural basis for the restriction of hepatitis B virus (HBV) entry in macaques, ...